1. Changes in folate concentration in Yoshida sarcoma after administration of leucovorin or cisplatin

   • Kenji Omura
   • Takuro Misaki
   • Tetsuhiko Shirasaka

   Original Article Pages: 183 - 187

2. Vinblastine and erythromycin: an unrecognized serious drug interaction

   • Sheldon W. Tobe
   • Lillian L. Siu
   • Ellen Warner

   Original Article Pages: 188 - 190

3. Intracellular pharmacodynamic studies of the synergistic combination of 6-mercaptopurine and cytosine arabinoside in human leukemia cell lines

   • Lilibeth V. Ramilo-Torno
   • Vassilios I. Avramis

   Original Article Pages: 191 - 199

4. In vivo screening models of cisplatin-resistant human lung cancer cell lines using SCID mice

   • Yuji Heike
   • Minako Takahashi
   • Nagahiro Saijo

   Original Article Pages: 200 - 204

5. Phase I study of phosphonacetyl-l-aspartate, 5-fluorouracil, and leucovorin in patients with advanced cancer

   • Alexandre Hageboutros
   • Andre Rogatko
   • Peter J. O'Dwyer

   Original Article Pages: 205 - 212

6. Daunorubicin and daunorubicinol pharmacokinetics in plasma and tissues in the rat

   • Barry J. Cusack
   • Stephan P. Young
   • Richard D. Olson

   Original Article Pages: 213 - 218

7. Phase I and pharmacology study of flavone acetic acid administered two or three times weekly without alkalinization

   • Marcel de Forni
   • Guy G. Chabot
   • Gonzalo Recondo

   Original Article Pages: 219 - 224

8. Treatment of advanced hormone-refractory prostate carcinoma with a combination of etoposide, pirarubicin and cisplatin

   • S. Naito
   • T. Ueda
   • Y. Fujisawa

   Original Article Pages: 225 - 229

9. Contrasting influence of peplomycin and azelastine hydrochloride (Azeptin) on reactive oxygen generation in polymorphonuclear leukocytes, cytokine generation in lymphocytes, and collagen synthesis in fibroblasts

   • Eisaku Ueta
   • Tokio Osaki
   • Tetsuya Yamamoto

   Original Article Pages: 230 - 236

10. Pharmacokinetics and pharmacodynamics of topotecan administered daily for 5 days every 3 weeks

    • Laurence J. C. van Warmerdam
    • Jaap Verweij
    • Jos H. Beijnen

    Original Article Pages: 237 - 245

11. Phase I study of RP 49532A, a new protein-synthesis inhibitor, in patients with advanced refractory solid tumors

    • Gilles Catimel
    • Régis Coquard
    • Michel Clavel

    Clinical Trial Report Pages: 246 - 248

12. Symptomatic, stage IV, non-small-cell lung cancer (NSCLC): response, toxicity, performance status change and symptom relief in patients treated with cisplatin, vinblastine and mitomycin-C

    • Diego Tummarello
    • Francesco Graziano
    • Riccardo Cellerino

    Clinical Trials Report Pages: 249 - 253

13. Effects of storage on the binding of carboplatin to plasma proteins

    • Kadir Erkmen
    • Merrill J. Egorin
    • James H. Doroshow

    Short Communication Pages: 254 - 256

14. Evaluation of anthracycline cardiotoxicity with the model of isolated, perfused rat heart: comparison of new analogues versus doxorubicin

    • Paul Pouna
    • Simone Bonoron-Adèle
    • Jacques Robert

    Short Communication Pages: 257 - 261

15. Inhibition of O⁶-alkylguanine-DNA alkyltransferase in animal and human ovarian tumor cell lines by O⁶-benzylguanine and sensitization to BCNU

    • Achim Magull-Seltenreich
    • Walter Jens Zeller

    Short Communication Pages: 262 - 266

16. The structure of P-glycoprotein and the secretion of lysosomal enzymes in multidrug-resistant cells

    • Leonard Warren
    • Anna Malarska
    • Jean-Claude Jardillier

    Short Communication Pages: 267 - 269